About ravulizuma b
Complement C5 inhibitor monoclonal antibody
Used for
- Paroxysmal nocturnal haemoglobinuria (PNH)
- Atypical haemolytic uraemic syndrome (aHUS)
- Generalised myasthenia gravis in certain adults
- Neuromyelitis optica spectrum disorder in certain adults
Usual adult dose
By intravenous infusion, based on body weight: a loading dose followed by maintenance doses every 4 or 8 weeks; regimen varies by condition and weight.
Usual dose in children
For aHUS, children weighing at least 10 kg may receive weight-based loading and maintenance infusions. Specialist dosing is required.
Common side effects
- Headache
- Upper respiratory infections
- Diarrhoea
- Nausea
Important warnings
- Can cause life-threatening meningococcal infection; vaccination is required before treatment when possible.
- Urgent antibiotics may be needed if treatment begins before vaccination protection develops.
- Seek urgent medical attention for fever, severe headache, rash, or confusion.
- Do not stop treatment without specialist supervision; the underlying condition may worsen.
Pregnancy
Use only when the potential benefit justifies possible fetal risk; pregnancy data are limited.
Breastfeeding
It is unknown whether ravulizumab passes into breast milk; discuss treatment and infant monitoring with a clinician.
Interactions
- Plasma exchange, plasmapheresis, and intravenous immunoglobulin can lower ravulizumab levels; supplemental doses may be needed.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.